Advaxis Company Profile (NASDAQ:ADXS)

About Advaxis

Advaxis logoAdvaxis, Inc. is a clinical-stage biotechnology company. The Company's immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company's immunotherapy candidates include Axalimogene filolisbac, ADXS-PSA and ADXS-HER2. Axalimogene filolisbac (ADXS-HPV) is a lead Lm-LLO immunotherapy product candidate for the treatment of human papilloma virus (HPV) associated cancers. ADXS-PSA is an Lm-LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (PSA) associated with prostate cancer. ADXS-HER2 is an Lm-LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADXS
  • CUSIP:
Key Metrics:
  • Previous Close: $10.54
  • 50 Day Moving Average: $12.23
  • 200 Day Moving Average: $9.56
  • 52-Week Range: $5.21 - $16.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.25
  • P/E Growth: 0.00
  • Market Cap: $428.32M
  • Outstanding Shares: 39,844,000
  • Beta: 1.48
Profitability:
  • Return on Equity: -64.51%
  • Return on Assets: -60.24%
Debt:
  • Current Ratio: 12.21%
  • Quick Ratio: 12.21%
Additional Links:
Companies Related to Advaxis:

Analyst Ratings

Consensus Ratings for Advaxis (NASDAQ:ADXS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.60 (127.57% upside)

Analysts' Ratings History for Advaxis (NASDAQ:ADXS)
Show:
DateFirmActionRatingPrice TargetDetails
9/9/2016Jefferies GroupReiterated RatingBuy$24.00View Rating Details
8/5/2016HC WainwrightReiterated RatingBuy$23.00View Rating Details
8/3/2016Barclays PLCBoost Price TargetOverweight$15.00 -> $20.00View Rating Details
7/7/2016FBR & CoReiterated RatingOutperform$34.00View Rating Details
12/17/2015Janney Montgomery ScottReiterated RatingBuy$22.00View Rating Details
9/11/2015GuggenheimInitiated CoverageBuy$30.00View Rating Details
6/26/2015MLV & Co.Initiated CoverageBuyView Rating Details
3/17/2015Noble FinancialReiterated RatingBuyView Rating Details
1/8/2015AegisReiterated RatingBuy -> PositiveView Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Advaxis (NASDAQ:ADXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/13/2016        
4/16/2015($0.31)($0.33)ViewN/AView Earnings Details
9/23/2014($0.25)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Advaxis (NASDAQ:ADXS)
Current Year EPS Consensus Estimate: $-1.83 EPS
Next Year EPS Consensus Estimate: $-2.06 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.61)($0.61)($0.61)
Q3 20161$0.55$0.55$0.55
Q4 20161($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Advaxis (NASDAQ:ADXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Advaxis (NASDAQ:ADXS)
Insider Ownership Percentage: 4.56%
Institutional Ownership Percentage: 55.57%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016David SidranskyDirectorSell22,808$15.01$342,348.08View SEC Filing  
8/8/2016Richard J BermanDirectorSell18,000$15.21$273,780.00View SEC Filing  
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.00View SEC Filing  
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87View SEC Filing  
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35View SEC Filing  
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25View SEC Filing  
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.00View SEC Filing  
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.46View SEC Filing  
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84View SEC Filing  
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12View SEC Filing  
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53View SEC Filing  
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88View SEC Filing  
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Advaxis (NASDAQ:ADXS)
DateHeadline
News IconAdvaxis' Lm Technology Immunotherapies to be Showcased in ... - PharmiWeb.com (press release) (NASDAQ:ADXS)
www.pharmiweb.com - September 27 at 6:46 AM
tmcnet.com logoAdvaxis' Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting (NASDAQ:ADXS)
www.tmcnet.com - September 26 at 8:21 PM
finance.yahoo.com logoAdvaxis’ Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting (NASDAQ:ADXS)
finance.yahoo.com - September 26 at 8:21 PM
News IconBiotech news that matter for investors: Keryx Biopharmaceuticals Inc ... - The Voice Registrar (NASDAQ:ADXS)
voiceregistrar.com - September 23 at 8:06 AM
News IconAnalysts Take the Wheel on Advaxis, Inc. (NASDAQ:ADXS) Shares ... - Frisco Fastball (NASDAQ:ADXS)
friscofastball.com - September 21 at 10:40 AM
News IconStock Under Review: Glori Energy Inc (NASDAQ:GLRI) , Advaxis, Inc. (NASDAQ:ADXS) - Wall Street Times (press release) (NASDAQ:ADXS)
www.wallstreetnews24.com - September 21 at 10:40 AM
News IconAdvaxis, Inc. (NASDAQ:ADXS) Given Average Recommendation of “Buy” from Analysts - DailyQuint (NASDAQ:ADXS)
dailyquint.com - September 20 at 3:19 PM
globenewswire.com logoAdvaxis to Present at the Aegis Annual Growth Conference - GlobeNewswire (press release) (NASDAQ:ADXS)
www.globenewswire.com - September 20 at 3:19 PM
finance.yahoo.com logoAdvaxis to Present at the Aegis Annual Growth Conference (NASDAQ:ADXS)
finance.yahoo.com - September 20 at 9:04 AM
marketexclusive.com logoA Timely Biotech Buy-Write - Advaxis, Inc. (NASDAQ:ADXS) - Market Exclusive (NASDAQ:ADXS)
marketexclusive.com - September 15 at 3:19 PM
capitalcube.com logoAdvaxis, Inc. – Value Analysis (NASDAQ:ADXS) : September 13, 2016 (NASDAQ:ADXS)
www.capitalcube.com - September 13 at 3:18 PM
finance.yahoo.com logoADVAXIS, INC. Financials (NASDAQ:ADXS)
finance.yahoo.com - September 13 at 3:18 PM
News IconNews review of 2 biotech stocks: Advaxis, Inc. (NASDAQ:ADXS), PDL BioPharma, Inc. (NASDAQ:PDLI) - The Voice Registrar (NASDAQ:ADXS)
voiceregistrar.com - September 13 at 8:05 AM
News IconShares Higher in Current Session: Advaxis, Inc. (NASDAQ:ADXS) - Post News (NASDAQ:ADXS)
www.kentuckypostnews.com - September 12 at 3:18 PM
capitalcube.com logoAdvaxis, Inc. breached its 50 day moving average in a Bearish Manner : ADXS-US : September 12, 2016 (NASDAQ:ADXS)
www.capitalcube.com - September 12 at 3:18 PM
finance.yahoo.com logoAdvaxis Unveils State-of-the-art Manufacturing Facility, Laboratory to Produce and Develop Novel Immuno-Oncology Therapeutics (NASDAQ:ADXS)
finance.yahoo.com - September 12 at 8:07 AM
News IconMarket Review: Watching Session Activity of Advaxis, Inc. (NASDAQ:ADXS) Shares - Post News (NASDAQ:ADXS)
www.kentuckypostnews.com - September 9 at 3:20 PM
publicnow.com logoN.J. Gov. Christie to Attend Advaxis Ribbon Cutting for New Manufacturing/Laboratory Facility in Princeton (NASDAQ:ADXS)
www.publicnow.com - September 8 at 3:20 PM
istreetwire.com logoInvestor's Alert: Advaxis, Inc. (ADXS), Merrimack Pharmaceuticals, Inc. (MACK), Ameren Corporation (AEE) - iStreetWire (NASDAQ:ADXS)
istreetwire.com - September 8 at 12:20 PM
News IconBiotech Stocks Worth a Closer Look: Advaxis, Inc. (NASDAQ:ADXS), Array BioPharma Inc. (NASDAQ:ARRY) - The Voice Registrar (NASDAQ:ADXS)
voiceregistrar.com - September 8 at 12:19 PM
biz.yahoo.com logoADVAXIS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:ADXS)
biz.yahoo.com - September 8 at 12:19 PM
finance.yahoo.com logoAdvaxis to Present at Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:ADXS)
finance.yahoo.com - September 6 at 8:07 AM
News IconInvestor Beat: Watching Activity of Advaxis, Inc. (NASDAQ:ADXS) Shares During the Session - Post News (NASDAQ:ADXS)
www.kentuckypostnews.com - September 3 at 8:07 AM
News IconTrading the Biotech News: Cempra, Inc. (NASDAQ:CEMP), Advaxis, Inc. (NASDAQ:ADXS) - The Voice Registrar (NASDAQ:ADXS)
voiceregistrar.com - September 1 at 3:20 PM
finance.yahoo.com logoADXS: Multiple Progresses Have Been Made (NASDAQ:ADXS)
finance.yahoo.com - August 25 at 8:46 PM
News IconAdvaxis, Inc. (NASDAQ:ADXS) Looks Like A Great Catalyst Pick (NASDAQ:ADXS)
streetregister.com - August 24 at 11:38 AM
biz.yahoo.com logoADVAXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ADXS)
biz.yahoo.com - August 23 at 8:39 PM
News IconAdvaxis, Inc. (NASDAQ:ADXS) Looks Like A Great Catalyst Pick - Street Register (NASDAQ:ADXS)
streetregister.com - August 23 at 9:16 AM
investornewswire.com logoWill Advaxis, Inc. (NASDAQ:ADXS) Hit $26 Price Target? - Investor Newswire (NASDAQ:ADXS)
www.investornewswire.com - August 21 at 8:06 AM
News IconPhRMA: 258 Vaccines in Clinical Development (NASDAQ:ADXS)
sciencebusiness.technewslit.com - August 20 at 8:03 AM
publicnow.com logoAdvaxis to Participate in Cervivor School (NASDAQ:ADXS)
www.publicnow.com - August 19 at 11:44 AM
streetinsider.com logoAdvaxis (ADXS) Reports $30M Direct Placement of Common Stock (NASDAQ:ADXS)
www.streetinsider.com - August 18 at 8:50 PM
News IconActive Stocks Need to Consider- Advaxis, Inc. (NASDAQ:ADXS ... - Seneca Globe (NASDAQ:ADXS)
www.senecaglobe.com - August 17 at 8:50 PM
biz.yahoo.com logoADVAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial Con (NASDAQ:ADXS)
biz.yahoo.com - August 16 at 8:38 PM
News IconBrixmor Property Group (NYSE:BRX) & Advaxis, Inc. (NASDAQ:ADXS) Trend Analysis Report - Money News (press release) (NASDAQ:ADXS)
www.newsismoney.com - August 13 at 3:19 PM
News IconHealthcare Stocks Lure Investment- Advaxis, Inc. (NASDAQ:ADXS ... - Seneca Globe (NASDAQ:ADXS)
www.senecaglobe.com - August 12 at 3:24 PM
streetinsider.com logoAdvaxis (ADXS) Says AXAL Met Phase 1 Primary Objective; Will Advance to Phase 2 (NASDAQ:ADXS)
www.streetinsider.com - August 11 at 9:11 PM
smarteranalyst.com logoCompany Update (NASDAQ:ADXS): Advaxis, Inc. Advances AXAL Into Second Stage of Phase 2 Clinical Study (NASDAQ:ADXS)
www.smarteranalyst.com - August 11 at 9:11 PM
smarteranalyst.com logoCompany Update (NASDAQ:ADXS): Advaxis, Inc. Advances AXAL Into Second Stage of Phase 2 Clinical Study - Smarter Analyst (NASDAQ:ADXS)
www.smarteranalyst.com - August 11 at 12:33 PM
publicnow.com logoAdvaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage (NASDAQ:ADXS)
www.publicnow.com - August 11 at 12:33 PM
fortune.com logoNotable Brokerage Recommendations: Advaxis, Inc. (NASDAQ:ADXS), AMN Healthcare Services, Inc. (NYSE:AHS) - Review Fortune (NASDAQ:ADXS)
reviewfortune.com - August 9 at 12:04 PM
News IconAdvaxis Inc (NASDAQ:ADXS) Forms Global Agreement with Amgen - Small Cap Exclusive (press release) (NASDAQ:ADXS)
smallcapexclusive.com - August 9 at 12:04 PM
istreetwire.com logo3 Notable Runners: Diamond Resorts International, Inc. (DRII), Advaxis, Inc. (ADXS), MannKind Corp. (MNKD) - iStreetWire (NASDAQ:ADXS)
istreetwire.com - August 8 at 8:06 AM
investornewswire.com logoStrong Sell Calls For Advaxis, Inc. (NASDAQ:ADXS) At 0 - Investor Newswire (NASDAQ:ADXS)
www.investornewswire.com - August 6 at 8:24 PM
News IconAnalyst Research and Ratings: Advaxis, Inc. (NASDAQ:ADXS), U.S. Silica Holdings, Inc. (NYSE:SLCA) - TWN (NASDAQ:ADXS)
thewellesleysnews.com - August 6 at 11:04 AM
News IconSecurities Analyst Recommendations: Advaxis, Inc. (NASDAQ:ADXS), Pfizer Inc. (NYSE:PFE) - TWN (NASDAQ:ADXS)
thewellesleysnews.com - August 6 at 11:04 AM
streetupdates.com logoAnalyst Rating Trends to Observe: Advaxis, Inc. (NASDAQ:ADXS) , Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Street Updates (NASDAQ:ADXS)
www.streetupdates.com - August 5 at 8:44 PM
News IconTrading the Biotech News: Advaxis, Inc. (NASDAQ:ADXS), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - The Voice Registrar (NASDAQ:ADXS)
voiceregistrar.com - August 5 at 8:44 PM
smarteranalyst.com logoBarclays Bumps Up Price Target on Advaxis, Inc. (ADXS) in the Wake of Amgen Deal - Smarter Analyst (NASDAQ:ADXS)
www.smarteranalyst.com - August 5 at 8:44 PM
smarteranalyst.com logoBarclays Bumps Up Price Target on Advaxis, Inc. (ADXS) in the Wake of Amgen Deal (NASDAQ:ADXS)
www.smarteranalyst.com - August 4 at 9:02 PM

Social

Advaxis (NASDAQ:ADXS) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff